Novel Combinations of Targeted Therapy for the Treatment of MLL Leukaemia
Grant number: 1066545 | Funding period: 2014 - 2017
Completed
Abstract
The poor prognosis conferred by chromosome breaks involving the MLL gene in acute leukaemia has not significantly changed in over twenty years. This fact highlights the urgent need to identify and develop novel therapeutic agents for this disease. This project will aim to understand the mechanisms leading to the initiation and maintenance of this aggressive disease. We will then use these insights to develop a rational combination of therapeutic agents.